3,292 Astrazeneca Plc $AZN Shares Sold by Quadrant Capital Group LLC

Quadrant Capital Group LLC lowered its position in shares of Astrazeneca Plc (NYSE:AZN) by 6.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,242 shares of the company’s stock after selling 3,292 shares during the quarter. Quadrant Capital Group LLC’s holdings in Astrazeneca were worth $7,361,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in AZN. Triumph Capital Management boosted its stake in Astrazeneca by 32.6% in the 3rd quarter. Triumph Capital Management now owns 252 shares of the company’s stock worth $41,000 after purchasing an additional 62 shares during the period. Riversedge Advisors LLC grew its position in Astrazeneca by 2.9% during the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock worth $379,000 after purchasing an additional 67 shares in the last quarter. Veery Capital LLC grew its position in Astrazeneca by 3.9% during the 3rd quarter. Veery Capital LLC now owns 1,857 shares of the company’s stock worth $300,000 after purchasing an additional 70 shares in the last quarter. Signal Advisors Wealth LLC grew its position in Astrazeneca by 2.7% during the 3rd quarter. Signal Advisors Wealth LLC now owns 2,778 shares of the company’s stock worth $448,000 after purchasing an additional 72 shares in the last quarter. Finally, Rosenberg Matthew Hamilton grew its position in Astrazeneca by 3.8% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 2,129 shares of the company’s stock worth $344,000 after purchasing an additional 78 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

AZN has been the topic of several recent analyst reports. Bank of America reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft raised Astrazeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Royal Bank Of Canada started coverage on Astrazeneca in a research report on Tuesday, September 8th. They issued an “outperform” rating for the company. HSBC downgraded Astrazeneca from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Finally, Zacks Research raised Astrazeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Fifteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $206.67.

Astrazeneca Price Performance

Shares of AZN opened at $168.97 on Wednesday. The company has a market capitalization of $262.05 billion, a price-to-earnings ratio of 16.89, a P/E/G ratio of 1.38 and a beta of 0.27. Astrazeneca Plc has a fifty-two week low of $153.41 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. The business’s 50-day moving average is $162.41 and its 200-day moving average is $175.46.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.13. The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a net margin of 17.02% and a return on equity of 31.45%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.17 earnings per share. Equities research analysts expect that Astrazeneca Plc will post 9.38 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.